

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Applicants : Walter Keith Jones
Serial No. : 10/596,513
Filed : December 16, 2008
Title : **OLIGONUCLEOTIDE DECOYS AND METHODS OF USE**
Docket : 10738-103
Examiner : Wu Cheng Winston Shen
Art Unit : 1632
Confirmation No. : 7508

DECLARATION UNDER 37 CFR §1.131

Sir:

I, Walter Keith Jones, declare and state:


1. I am the inventor of the above-identified patent application.
2. I am familiar with the Office Action mailed July 7, 2011, including the rejections made by the Examiner therein. I am also familiar with Dzau et al., United States Patent Application Publication US 2003/0186922 (hereafter, "Dzau"), which was cited by the Examiner against the above-identified patent application. Dzau first published October 2, 2003.
3. On a date prior to October 2, 2003, I conceived of the subject matter of claims 1-17 and 19-33 of this patent application. All of the acts reported below were carried out in the United States.
4. On December 19, 2003, I constructively reduced this invention to practice by filing a provisional patent application with the United States Patent & Trademark Office (USPTO). That application was given serial number 60/531,399 by the USPTO. At least from a time prior to October 2, 2003, the publication date of Dzau, until December 19, 2003, the U.S. filing date of the instant application, I was diligent in my efforts to pursue patent protection. Due diligence in reduction to practice is evidenced by the following acts carried out by myself or by others working under my direction and control:

5. On May 5, 2003, I discussed construction of the oligonucleotide decoy concatemers with my lab group, as evidenced by notes made in a lab notebook recording a summary of our meeting (Exhibit A).

6. On June 13, 2003, Dr. Suiwen He, working under my direction, placed orders for the first oligonucleotide starting materials to begin construction of the decoys, as evidenced by the order forms dated June 13, 2003 (Exhibit B).

7. From the time the oligonucleotide starting materials were received, until the date of our constructive reduction to practice by virtue of the filing of U.S. Provisional Application 60/531,399 on December 19, 2003, Dr. Suiwen He continued to work, under my direction and control, on constructing the oligonucleotide decoys of the instant claims, as evidenced by an email sent to me by Dr. He on November 5, 2003, providing a status update (Exhibit C).

8. Further, I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application and any patent issued thereon.



Walter Keith Jones

EXHIBIT A

cell transfection

0.01 mg/ml : smallest particle
made

We need $30 \mu\text{g}/\mu\text{l}$ \rightarrow $1 \mu\text{g}/\mu\text{l}$
($30 \text{ mg}/\text{ml}$)

300 nm \rightarrow $5-900 \text{ nm}$ plasmid

\rightarrow a
Rhodamine \rightarrow real
time
data

Polymer sitting in the cell.
Labeling Polymer / DNA

PCR the concatemer

I'll do engineering concatemer
light scattering

1) Toxicology

2) Concatemer wrapped by polymer

3) Cell culture HeLa cardiac cell

4)


2 cm²
sa cm²

-toxic

5-5-03 : Lab Meeting:

TNF- α \rightarrow JNK.

{ p38 antibody.
erk



Western: { ① 2M. pc. mRNA again
small infarct region
② Protein made or not.

{ iNOS Western: Bollik..
Guo: K/O paper }
more iNOS \uparrow 3 fold in WT/PC after 24hr.

{ make pcr on groups having @ too much
variation (2 groups)

{ A.G. }

{ Western } { iNOS }

Finish Western.

iNOS
antibody.

Antibody { ① Geyrol Tindler
② Santa Cruz

Transduction Laboratory. Santa Cruz

5-12-03 : Lab Meeting: Theresa M. Reineke.
Department of Chemistry.

Nonviral Vectors:

no limit to gene size

20 \sim \leq 300 nm

endosome

DNA through nucleus membrane.

{ chitosan } / PEI mixture.

Polyplexes (poly + DNA)

Lipoplexes (lipid + DNA)

PEI: toxic

Chitosan: non-toxic

EXHIBIT B

University of Cincinnati DNA Core

2302 Medical Sciences Building

Mail Location: 0524

Cincinnati, Oh 45267-0524

WWW.MOLGEN.UC.EDU/DNACORE/INDEX.HTM

Phone: 513-558-5520

Fax: 513-558-8474

User Name: SUIWEN HE/W. KEITH JONES

Phone: 558-2356

Department: PHARMACOLOGY

Synthesis Date: 6/13/2003

Email address: HESN@EMAIL.UC.EDU

Lab Location: CVC 5940

Fund/PO #: PHARMACOLOGY

Options Selected

Selected Scale: ☐ 10 nmol DNA ☐ repurify
☐ 40 nmol DNA ☐ 0.2 umol RNA
☒ 0.2 umol DNA ☐ 1.0 umol RNA
☐ 1.0 umol DNA

Purification: ☒ none
☐ 10 nmol desalt
☐ desalting
☐ gel purify

Oligo Id #: 77969 : TANDEM-NFS

Length 38nt

Sequence:

5'> CCGGAATTCCCTTGAAGGGATTTCCTCCGGATCCGCG

Molec. Weight: 12391.6 g/mol Tm 122°C Previous ID #

Previous weight

***** Analysis Results *****

Stepwise Yield: 98.7 %
Overall Yield: 61.1 %
Amount of DNA: 954.03 ug
(in eppendorf tube)
Ratio A260/A280: 1.316
Column Lot #: G-MEM

*** Cost Summary ***

Cost of Oligonucleotide: \$45.60
Cost of Purification: \$0.00
Specialty fee:
Shipping
Total Charge: \$45.60

We offer online ordering! Save yourself a trip to the DNA Core
And remember...we deliver!

University of Cincinnati DNA Core

2302 Medical Sciences Building
Mail Location: 0524
Cincinnati, Oh 45267-0524

WWW.MOLGEN.UC.EDU/DNACORE/INDEX.HTM
Phone: 513-558-5520
Fax: 513-558-8474

User Name: SUIWEN HE/W. KEITH JONES

Phone: 558-2356

Department: PHARMACOLOGY

Synthesis Date: 6/13/2003

Email address: HESN@EMAIL.UC.EDU

Lab Location: CVC 5940

Fund/PO #: PHARMACOLOGY

Options Selected

Selected Scale:

- ☐ 10 nmol DNA ☐ repurify
☐ 40 nmol DNA ☐ 0.2 umol RNA
☒ 0.2 umol DNA ☐ 1.0 umol RNA
☐ 1.0 umol DNA

Purification:

- ☒ none
☐ 10 nmol desalt
☐ desalting
☐ gel purify

Oligo Id #: 77970 : TANDEM-NFA

Length 38nt

Sequence:

5'> CGCGGATCGGAGGGGAAATCCCTTCAAGGGAATTCCGG

Molec. Weight: 12586.6 g/mol Tm 122°C Previous ID #

Previous weight

***** Analysis Results *****

Stepwise Yield : 99.6 %
Overall Yield: 87.7 %
Amount of DNA: 1115.07 ug
(in eppendorf tube)
Ratio A260/A280: 1.544
Column Lot #: G-MEM

*** Cost Summary ***

Cost of Oligonucleotide: \$45.60
Cost of Purification: \$0.00
Specialty fee:
Shipping
Total Charge: \$45.60

We offer online ordering! Save yourself a trip to the DNA Core.
And remember...we deliver!

EXHIBIT C

Date: Wed, 5 Nov 2003 21:35:55 -0800 (PST)
From: Suiwen He <suiwenhe@yahoo.com>
Subject: Re: Thurs
To: Keith Jones <joneswk@uc.edu>
MIME-Version: 1.0

Boss,

I am leaving on Thursday and back to lab on Nov. 18 as I will go to Washington DC and Baltimore for several days after the meeting.

I did the acrylamide gel to purify the annealed decoy after RI/BamHI digestion and it looked good. I also showed Maria about the gel. I gel purified it and also the vector part. They are both ready to go after I come back for ligation.

My cell phone is 513-237-9801. There seem to be a lot of interesting topics in the meeting as I went over the info.

Please call me if you have any questions about the lab. I will bring back the 12 copies of CT journal.

S. He

=====

Suiwen He, M.D., Ph.D., Postdoctoral Fellow
Department of Pharmacology and Cell Biophysics
University of Cincinnati College of Medicine
231 Albert B. Sabin Way
CVC Bldg, Rm 5940
Cincinnati, OH 45267-0575
(513) 237-9801 (Cell), (513) 558-2356 (Lab and Office)

Do you Yahoo!?

Protect your identity with Yahoo! Mail AddressGuard
<http://antispam.yahoo.com/whatsnewfree>